Mastic Gum: The Tree Resin That Kills H. pylori — And About a Dozen Other Things

New name   B I U S link H1 H2 H3 list 1. x2 x2 page image code pre HTML center hr table note notes desc ▲ ▼	Show page  Syntax
{html}<article> <header> <p class="lede">It's not even gum. It's resin scraped off a tree on a Greek island. And in a 1998 <em>New England Journal of Medicine</em> letter, it killed the bacterium that causes most stomach ulcers. That was the start. What came after — dyspepsia trials, Crohn's data, cholesterol work, cancer-cell studies — is weirder than the original discovery.</p> </header> <section> <h2>The list, before we get into it</h2> <p>Read this slowly. Most of these are real, peer-reviewed findings. Some are in humans. Some are in cells in a dish. I'll separate them honestly below, because the difference matters.</p> <ul> <li><strong>Stomach / gut (human data):</strong> killed <em>H. pylori</em>, the ulcer bacterium; cleared it in roughly 1 in 3 people without antibiotics; improved functional dyspepsia in 77% vs 40% on placebo; reported to heal peptic ulcers.</li> <li><strong>Inflammatory bowel disease (human data, early):</strong> reduced inflammation and symptom severity in Crohn's disease; reduced inflammatory markers in inflammatory bowel disease.</li> <li><strong>Cardiovascular (human data):</strong> lowered total and LDL cholesterol; helped protect LDL from oxidizing.</li> <li><strong>Oral (human data):</strong> reduced dental plaque; killed oral bacteria.</li> <li><strong>Cancer (cell / pre-clinical only — not yet in humans):</strong> killed colon cancer cells; killed prostate cancer cells; stopped leukemia cells; blocked tumor blood-vessel formation.</li> <li><strong>Industrial / surgical:</strong> used as a base for surgical skin adhesive.</li> </ul> <p>I read that list three times before I started writing this. The stomach part is the part that's actually been tested in people. The cancer part is cells in a lab. I'll keep them clearly labelled.</p> </section> <section> <h2>First: what mastic gum actually is</h2> <p>Mastic gum is the dried resin of <em>Pistacia lentiscus</em> var. <em>chia</em>, a small evergreen tree in the pistachio family. It's harvested almost exclusively on the Greek island of Chios, where the trees are slashed and the resin that oozes out is left to dry into teardrop-shaped "tears." It's been chewed as a breath freshener and used as a folk stomach remedy in the eastern Mediterranean for at least 2,500 years. The European Medicines Agency has registered Chios mastic as a traditional herbal medicine for mild dyspeptic and gastrointestinal disorders — which is a polite, regulator-grade way of saying "people have used this for upset stomachs for a very long time, and it's safe enough that we're not going to stop them."</p> <p>It's not a chewing gum base, despite the name. The "gum" in the name is older English usage for any resinous exudate. The relevant molecule family is mostly triterpenes — masticadienonic acid, isomasticadienonic acid, oleanolic acid, and a handful of related compounds — which is what keeps showing up when researchers try to explain why this stuff does what it does.</p> </section> <section> <h2>The 1998 NEJM letter that started everything</h2> <p>The main article that kicked off the modern interest is a short correspondence published in the <em>New England Journal of Medicine</em> on December 24, 1998, by F. U. Huwez, D. Thirlwell, and A. Cockayne, working at Barnet General Hospital in the UK. The title is plain: <a href="https://www.nejm.org/doi/full/10.1056/NEJM199812243392618">"Mastic Gum Kills Helicobacter pylori."</a></p> <p>The letter is short but specific. The authors reported that mastic gum was bactericidal against <em>H. pylori</em> in the test tube at concentrations that were realistically achievable in the stomach, and that even low doses — <strong>1 g per day for two weeks</strong> — could cure peptic ulcers very rapidly in their clinical observation. (A small correction ran in NEJM in February 1999: the original letter had said "1 mg per day," which was a typo. The intended dose was 1 g per day. If you ever see mastic dosing quoted in milligrams-per-day from the 1998 paper, that's the source of the error.)</p> <p>Why this mattered: <em>H. pylori</em> is the organism that Barry Marshall and Robin Warren had identified in 1982 as the cause of most peptic ulcers — work that won them the 2005 Nobel Prize. By 1998, the standard treatment was a multi-drug antibiotic cocktail (the "triple therapy"), which worked but had side effects, growing resistance, and a non-trivial failure rate. The idea that a tree resin eaten as a folk remedy for centuries might kill the same bacterium — at doses you could swallow in capsules — was a genuine surprise.</p> <p>The mechanism, the authors noted, was not yet established. That gap is still partly open today.</p> </section> <section> <h2>Does it actually clear <em>H. pylori</em> in real people?</h2> <p>The 1998 NEJM letter was a clinical observation, not a randomized trial. The question of whether mastic <em>alone</em> could clear an established <em>H. pylori</em> infection in a controlled setting was answered a decade later by Dabos and colleagues, in a randomized pilot study published in <em>Phytomedicine</em> in 2010 (PubMed <a href="http://pubmed.ncbi.nlm.nih.gov/19879118/">19879118</a>).</p> <p>That trial enrolled 52 patients with confirmed <em>H. pylori</em> infection and randomized them to one of three groups: 350 mg of pure mastic gum three times a day for 14 days, 1.05 g of pure mastic gum three times a day for 14 days, or standard antibiotic therapy. The headline result was modest but real: roughly <strong>1 in 3 patients</strong> on mastic alone cleared the infection — about 30.8% in the lower-dose arm — compared with antibiotics clearing roughly 10 of 13 in the comparator arm. Mastic was well tolerated across both doses, with no serious adverse events reported.</p> <p>So, translated into plain English: mastic alone is not a replacement for antibiotics. It clears about a third of infections on its own. Antibiotics clear about three-quarters. That's not a contest mastic wins — but it's a striking result for an unrefined plant resin taken as a capsule.</p> <p>More recent work has tested mastic <em>as an add-on</em> to standard therapy rather than as a standalone. In a 2023 trial (Addissouky and colleagues), combining mastic with standard triple antibiotic therapy raised eradication rates from 63% to 92% — i.e., roughly a third of patients who would have failed standard therapy cleared the infection when mastic was added. A 2026 pilot in the <em>Indian Journal of Gastroenterology</em> tested the same add-on idea against bismuth quadruple therapy, with symptom scores moving more clearly than eradication did. This is the more clinically interesting direction: not "mastic instead of antibiotics," but "mastic with antibiotics."</p> <p>One important negative finding: a small study combining mastic with the proton-pump inhibitor pantoprazole showed zero eradication, which suggests mastic may not work the same way in the presence of strong acid suppression. The interaction is not well worked out, and it's a real reason not to assume mastic will "just work" alongside every gut medication.</p> </section> <section> <h2>The 77% vs 40% dyspepsia trial — this is where mastic actually shines</h2> <p>If the <em>H. pylori</em> eradication data is "encouraging but modest," the functional dyspepsia data is genuinely strong. Functional dyspepsia is the modern name for chronic indigestion — bloating, upper-abdominal pain or burning, early fullness — that persists after ulcers, <em>H. pylori</em>, and other identifiable causes have been ruled out. It's common, it's frustrating, and conventional treatment helps only some of the people who have it.</p> <p>In 2010, Dabos and colleagues ran a prospective, randomized, double-blind, placebo-controlled trial of Chios mastic gum in functional dyspepsia, published in the <em>Journal of Ethnopharmacology</em> (PubMed <a href="http://pubmed.ncbi.nlm.nih.gov/19961914/">19961914</a>). They enrolled 148 patients meeting Rome II criteria for functional dyspepsia. Patients received either 350 mg of mastic gum three times a day (1.05 g total daily) or placebo, for three weeks.</p> <p>The result: <strong>77% of patients on mastic reported marked improvement in symptoms, versus 40% on placebo</strong> (p &lt; 0.02). The symptoms that improved most were stomach pain, dull upper-abdominal ache, and heartburn. Notably, stress-triggered stomach pain also improved — which fits a condition that has a well-recognized gut-brain component.</p> <p>A second, smaller trial followed in 2025 in <em>Pharmacological Research</em>, using a three-way crossover design and the newer Rome IV criteria. Patients rotated through 1.4 g/day of mastic capsules, 20 ml/day of "Mastiha water" (the distillate left over from mastic processing), and a no-treatment comparison period, with a 14-day washout between phases. Both mastic forms improved symptoms relative to the no-intervention period; capsules specifically reduced bloating, epigastric burning, and heartburn. The 2025 trial is weaker evidence than the 2010 one — the comparison was no treatment rather than placebo — but it's a real replication, and replications are what separate a one-off from a real effect.</p> <p>This is the claim the data actually carries best. Symptom relief in functional dyspepsia is not the same as curing <em>H. pylori</em>; it's a softer endpoint. But it's also the endpoint that matters most if you're the person who's been bloated and burning after every meal for months.</p> </section> <section> <h2>The stomach ulcer observation</h2> <p>The original 1998 NEJM letter from Huwez and colleagues was based on clinical observation that even low doses — 1 g per day for two weeks — appeared to resolve peptic ulcers rapidly. This is the original "heals stomach ulcers" claim in the list above. It's a clinician's observation from a single site, not a randomized trial, and it predates the rigorous <em>H. pylori</em> eradication work. Treat it as the historical seed of the modern research, not as the strongest evidence in the stack.</p> </section> <section> <h2>Crohn's disease and IBD</h2> <p>Two papers here, both human. The Crohn's work (PubMed <a href="http://pubmed.ncbi.nlm.nih.gov/17278198/">17278198</a>) was a small clinical trial of mastic in patients with active Crohn's disease, examining its effect on inflammatory markers and symptom severity. The IBD paper (PubMed <a href="http://pubmed.ncbi.nlm.nih.gov/30450689/">30450689</a>) examined mastic's effect on inflammatory pathways relevant to inflammatory bowel disease more broadly — work that connects to the well-documented anti-inflammatory action of mastic triterpenes on the NF-κB signaling pathway, which sits upstream of much of the inflammation in IBD.</p> <p>Both are early-stage. Neither is a large, multi-center, registration-grade trial. But the direction is consistent: mastic appears to reduce inflammation in inflammatory bowel conditions, and the mechanism is biologically plausible. This is firmly in "interesting, needs more work, talk to your gastroenterologist before adding it to a real IBD regimen" territory.</p> </section> <section> <h2>Cholesterol and LDL oxidation</h2> <p>The cholesterol work (PubMed <a href="http://pubmed.ncbi.nlm.nih.gov/17150319/">17150319</a>) was a human trial showing reductions in total and LDL cholesterol with mastic supplementation. There is also evidence — from related work on mastic triterpenes — that mastic helps protect LDL particles from oxidizing. Oxidized LDL, not native LDL, is the form that drives atherosclerotic plaque formation, so an effect on oxidation is mechanistically distinct from and complementary to a pure lipid-lowering effect.</p> <p>This is a meaningful but modest cardiovascular signal. It does not replace statins, diet, or exercise. It is the kind of result that, if you already have borderline cholesterol and are looking for an additional lever, puts mastic on the short list of things worth trying.</p> </section> <section> <h2>Dental plaque and oral bacteria</h2> <p>Given that <em>H. pylori</em> also colonizes the oral cavity (and that the oral cavity is a recognized reservoir for re-infection after stomach eradication), the oral findings are not a curiosity — they may be part of the same story. Mastic and mastic oil have been shown in human studies to reduce dental plaque and to be antibacterial against oral pathogens. This is one of the older traditional uses of mastic — chewing the resin as a breath freshener — and the modern data simply confirms what folk practice asserted.</p> </section> <section> <h2>The cancer studies — and the very large asterisk on them</h2> <p>Here is where the honesty matters most. Every cancer claim on the list above comes from <strong>cell-line and pre-clinical work, not from human trials</strong>. There is no human evidence that mastic gum treats, cures, or prevents cancer. What there is, is a series of laboratory studies showing that mastic or its isolated triterpenes are cytotoxic to specific cancer cell lines:</p> <ul> <li><strong>Colon cancer cells</strong> (PubMed <a href="http://pubmed.ncbi.nlm.nih.gov/15796160/">15796160</a>): mastic extract induced cell death in colon cancer cell lines in vitro. The mechanism involves induction of apoptosis (programmed cell death) in the cancer cells.</li> <li><strong>Prostate cancer cells</strong> (PubMed <a href="http://pubmed.ncbi.nlm.nih.gov/16691616/">16691616</a>): mastic extract was cytotoxic to prostate cancer cell lines, again via apoptotic pathways.</li> <li><strong>Leukemia cells and tumor blood vessels</strong> (PubMed <a href="http://pubmed.ncbi.nlm.nih.gov/16965245/">16965245</a>): mastic extract was cytotoxic to leukemia cell lines <em>and</em> inhibited angiogenesis — the formation of new blood vessels that tumors need to grow beyond a small size. Anti-angiogenic activity is a recognized anti-cancer strategy (it's how several approved cancer drugs work), so finding it in a plant resin is genuinely interesting.</li> </ul> <p>What this means: mastic contains compounds that, in a petri dish, kill cancer cells and block the blood supply tumors need. It does <em>not</em> mean mastic cures cancer in a person. Many compounds kill cancer cells in a dish and then fail in humans, either because they can't reach the tumor at high enough concentrations or because the body metabolizes them differently. What it does mean is that mastic is a legitimate subject for oncology research, and that its active compounds are reasonable candidates for drug development.</p> <p>If anyone is selling mastic as a cancer treatment on the basis of these studies, they are overreading the evidence. If a research group is studying mastic triterpenes as lead compounds for new oncology drugs, they are doing exactly the right thing with this data.</p> </section> <section> <h2>Surgical adhesive — the strange footnote</h2> <p>The "used in surgical skin glue" line on the list is the one that sounds most like an urban legend and is, in fact, real. Mastic and related Pistacia resins have a very long history of use as an adhesive and wound-sealant in the eastern Mediterranean — they were used to seal wounds in antiquity. Modern work has revisited mastic and related natural resins as components of surgical adhesives and tissue glues, an area of active materials-science research. This is not a health claim; it's a materials-science footnote. But it tells you something about how unusual this resin is: the same stuff that kills ulcer bacteria in a test tube also has the chemical properties of a wound-closing glue.</p> </section> <section> <h2>What the evidence does <em>not</em> show</h2> <p>It's worth being explicit about what the data doesn't support, so the rest doesn't get oversold:</p> <ul> <li>Mastic alone is <strong>not</strong> a substitute for antibiotic eradication of <em>H. pylori</em>. It clears about a third of infections on its own; antibiotics clear about three-quarters.</li> <li>There is <strong>no</strong> randomized trial of mastic for GERD (gastroesophageal reflux disease) or for erosive esophagitis. Heartburn was measured as one symptom of dyspepsia, not as reflux disease. If you have actual reflux disease, mastic is not your evidence-based answer.</li> <li>There is <strong>no human evidence</strong> that mastic treats cancer. The cancer findings are cell-line and pre-clinical only.</li> <li>Mastic may <strong>not work the same way</strong> in the presence of strong acid-suppression medication (the pantoprazole interaction). If you're on a PPI, this is not a "more is better" situation.</li> <li>The European Medicines Agency monograph — the regulator that has actually registered mastic as a traditional herbal medicine — advises seeing a doctor if digestive symptoms last beyond two weeks. That's the right caution.</li> </ul> </section> <section> <h2>Personal footnote</h2> <p>Three months of heartburn. Gone in a week. That's not a clinical trial; it's one person's report, and it's why I started reading the literature in the first place. The reason I'm sharing it is that the 2010 dyspepsia trial — 77% on mastic versus 40% on placebo, with heartburn specifically named as one of the symptoms that improved — makes a one-week resolution in a single person not a miracle, just a data point that lands on the right side of the distribution.</p> </section> <section> <h2>Bottom line: if you wanted to act on this today, what can we do</h2> <p>If your situation is "I have chronic heartburn, bloating, or indigestion and over-the-counter antacids aren't cutting it," the evidence-based move is:</p> <ol> <li><strong>Get tested for <em>H. pylori</em>.</strong> It's a breath or stool test, it's cheap, and the infection is treatable. If you're positive, talk to your doctor about standard eradication therapy <em>and</em> ask whether adding mastic is reasonable in your case — the add-on data is genuinely promising.</li> <li><strong>If you're <em>H. pylori</em>-negative and the diagnosis is functional dyspepsia</strong>, the 2010 trial is the one to point to. The trial dose was 350 mg of pure Chios mastic, three times a day, for three weeks. Use pure mastic powder or capsules — not mastic-flavored chewing gum, which is a different product. The EMA monograph on Chios mastic is the regulatory reference your doctor can look up if they're unfamiliar.</li> <li><strong>Set a checkpoint.</strong> Give it two to three weeks. If symptoms haven't moved, stop — and reconsider the diagnosis, because "indigestion" can hide reflux disease, gallbladder issues, or, rarely, something more serious. The EMA two-week rule is a reasonable safety net.</li> <li><strong>If you're on a PPI or other acid-suppression medication</strong>, talk to your doctor before adding mastic — the pantoprazole interaction is a real flag, not a theoretical one.</li> <li><strong>For everything else on the list — cholesterol, IBD, oral health, the cancer-cell findings</strong> — treat mastic as a reasonable dietary inclusion, not as a therapy. The strongest human data is for the stomach. Everything else is interesting, ongoing research, and in some cases (cancer) explicitly pre-clinical.</li> </ol> <p>The honest summary: mastic gum is a real, traditionally used, regulator-recognized resin with surprisingly solid human data for functional dyspepsia and a meaningful — but not antibiotic-replacing — effect on <em>H. pylori</em>. The rest of the list is real research, mostly early, and in the cancer case entirely pre-clinical. Take the stomach part seriously. Take the cancer part as a reason to watch the oncology literature, not as a reason to skip an oncologist.</p> </section> <section> <h2>Sources</h2> <ul class="sources"> <li>Huwez FU, Thirlwell D, Cockayne A. <a href="https://www.nejm.org/doi/full/10.1056/NEJM199812243392618"><em>Mastic Gum Kills Helicobacter pylori</em></a>. New England Journal of Medicine. 1998;339(26):1946. doi:10.1056/NEJM199812243392618. <em>(The main article.)</em></li> <li>NEJM correction (dose clarification, 1 mg → 1 g): N Engl J Med. 1999;340:723. <a href="https://www.nejm.org/doi/full/10.1056/NEJM199902183400723">10.1056/NEJM199902183400723</a></li> <li>Dabos KJ, et al. <em>The effect of mastic gum on Helicobacter pylori: a randomized pilot study.</em> Phytomedicine. 2010. <a href="http://pubmed.ncbi.nlm.nih.gov/19879118/">PubMed 19879118</a> <em>(The "1 in 3 cleared it on mastic alone" trial.)</em></li> <li>Dabos KJ, et al. <em>Is Chios mastic gum effective in the treatment of functional dyspepsia? A prospective randomised double-blind placebo controlled trial.</em> J Ethnopharmacol. 2010. <a href="http://pubmed.ncbi.nlm.nih.gov/19961914/">PubMed 19961914</a> <em>(The 77% vs 40% dyspepsia trial.)</em></li> <li>Crohn's disease trial: <a href="http://pubmed.ncbi.nlm.nih.gov/17278198/">PubMed 17278198</a></li> <li>Inflammatory bowel disease study: <a href="http://pubmed.ncbi.nlm.nih.gov/30450689/">PubMed 30450689</a></li> <li>Cholesterol / LDL trial: <a href="http://pubmed.ncbi.nlm.nih.gov/17150319/">PubMed 17150319</a></li> <li>Colon cancer cells (in vitro): <a href="http://pubmed.ncbi.nlm.nih.gov/15796160/">PubMed 15796160</a></li> <li>Prostate cancer cells (in vitro): <a href="http://pubmed.ncbi.nlm.nih.gov/16691616/">PubMed 16691616</a></li> <li>Leukemia cells and tumor angiogenesis (in vitro / pre-clinical): <a href="http://pubmed.ncbi.nlm.nih.gov/16965245/">PubMed 16965245</a></li> <li>European Medicines Agency. <em>European Union herbal monograph on Pistacia lentiscus L., resina (mastic).</em></li> </ul> </section> </article>{/html}
Password  Summary of changes

 📜 ⏱️ ⬆️